A Systematic review and Meta-Analysis of the survival and clinicopathological features of p63 expression in Merkel cell carcinoma
Corresponding Author
Nataly Portilla
Dermatology Department, Clínica Erasmo, Valledupar, Colombia
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Both authors have equally contributed.Correspondence: Nataly Portilla Dermatology Department, Clínica Erasmo, Cra. 19 Nº 4C-72. Valledupar, Colombia. Email: [email protected]
Rafael Parra-Medina, Research Institute, Fundación Universitaria de Ciencias de la Salud, Carrera 52 # 67A-71. Bogotá, Colombia. Email: [email protected]
Search for more papers by this authorJuan P. Alzate
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Search for more papers by this authorFabio A. Sierra
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Search for more papers by this authorCorresponding Author
Rafael Parra-Medina
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Pathology Department, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Both authors have equally contributed.Correspondence: Nataly Portilla Dermatology Department, Clínica Erasmo, Cra. 19 Nº 4C-72. Valledupar, Colombia. Email: [email protected]
Rafael Parra-Medina, Research Institute, Fundación Universitaria de Ciencias de la Salud, Carrera 52 # 67A-71. Bogotá, Colombia. Email: [email protected]
Search for more papers by this authorCorresponding Author
Nataly Portilla
Dermatology Department, Clínica Erasmo, Valledupar, Colombia
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Both authors have equally contributed.Correspondence: Nataly Portilla Dermatology Department, Clínica Erasmo, Cra. 19 Nº 4C-72. Valledupar, Colombia. Email: [email protected]
Rafael Parra-Medina, Research Institute, Fundación Universitaria de Ciencias de la Salud, Carrera 52 # 67A-71. Bogotá, Colombia. Email: [email protected]
Search for more papers by this authorJuan P. Alzate
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Search for more papers by this authorFabio A. Sierra
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Search for more papers by this authorCorresponding Author
Rafael Parra-Medina
Research Institute, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Pathology Department, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Both authors have equally contributed.Correspondence: Nataly Portilla Dermatology Department, Clínica Erasmo, Cra. 19 Nº 4C-72. Valledupar, Colombia. Email: [email protected]
Rafael Parra-Medina, Research Institute, Fundación Universitaria de Ciencias de la Salud, Carrera 52 # 67A-71. Bogotá, Colombia. Email: [email protected]
Search for more papers by this authorAbstract
Merkel cell carcinoma (MCC) is a rare skin tumour of neuroendocrine origin with aggressive behaviour. The aims of this study were to investigate the association of p63 + MCC with clinicopathological features and to estimate survival through a systematic review and meta-analysis. A comprehensive search of PubMed, Embase, Scopus and Virtual Health Library following the PRISMA guidelines was conducted on September 2017. DerSimonian and Lard random-effects models were used to calculate survival-weighted means and their corresponding 95% confidence intervals (CI) among studies. Five studies met our inclusion criteria after screening 77 citations and 36 full-text articles. The included studies enrolled 413 patients with MCC. We observed that p63 + MCC was significantly associated with mortality with OR 2.92 (95% CI [1.66–5.13]). The summary hazard ratio of multivariate analysis was 1.99 (95% CI [1.32–3.01]). The only clinicopathological feature associated with p63 + MCC with statistical significance was the Merkel cell polyomavirus (MCPyV) status. The presence of MCPyV was associated as a protective factor for the expression of p63 (OR 0.25, 95% CI [0.08–0.73]). These results support that p63 + MCC evaluated by immunohistochemistry has a poor outcome. Therefore, we suggest p63 to be performed when staging MCC.
Supporting Information
| Filename | Description |
|---|---|
| ajd13211-sup-0001-TableS1.docxWord document, 16 KB | Table S1. Joanna Briggs Institute risk of bias tool assessment |
| ajd13211-sup-0002-Supinfo.pdfPDF document, 23.1 KB | Data S1. Terms of the search strategy |
| ajd13211-sup-0003-FigureS1.pdfPDF document, 58.2 KB | Figure S1. Flow Diagram |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Albores-Saavedra J, Batich K, Chable-Montero F et al. "Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study," (in eng). J. Cutan. Pathol. 2010; 37: 20–7.
- 2Lim CS, Whalley D, Haydu LE et al. "Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma," (in eng). Ann. Surg. Oncol. 2012; 19: 3325–34.
- 3Busam KJ, Jungbluth AA, Rekthman N, et al. "Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas," (in eng). Am. J. Surg. Pathol. 2009; 33: 1378–85.
- 4Allen PJ, Bowne WB, Jaques DP et al. "Merkel cell carcinoma: prognosis and treatment of patients from a single institution," (in eng). J. Clin. Oncol. 2005; 23: 2300–9.
- 5Feng H, Shuda M, Chang Y et al. "Clonal integration of a polyomavirus in human Merkel cell carcinoma," (in eng). Science 2008; 319: 1096–100.
- 6Heath M, Jaimes N, Lemos B, et al. "Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features," (in eng). J. Am. Acad. Dermatol. 2008; 58: 375–81.
- 7Asioli S, Righi A, Volante M et al. "p63 expression as a new prognostic marker in Merkel cell carcinoma," (in eng). Cancer 2007; 110: 640–7.
- 8Carson HJ, Reddy V, Taxy JB. "Proliferation markers and prognosis in Merkel cell carcinoma," (in eng). J. Cutan. Pathol. 1998; 25: 16–9.
- 9Feinmesser M, Halpern M, Fenig E, et al. "Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?," (in eng). Hum. Pathol. 1999; 30: 1367–72.
- 10Kennedy MM, Blessing K, King G et al. Expression of bcl-2 and p53 in Merkel Cell Carcinoma. Am. J. Dermatopathol. 1996; 18: 273–77.
- 11Sihto H, Kukko H, Koljonen V et al. "Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma," (in eng). Clin Cancer Res 2011; 17: 4806–13.
- 12Di Como CJ, Urist MJ, Babayan I et al. "p63 expression profiles in human normal and tumor tissues," (in eng). Clin. Cancer Res. 2002; 8: 494–501.
- 13Lo Muzio L, Santarelli A, Caltabiano R, et al. "p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma," (in eng). Hum. Pathol. 2005; 36: 187–94.
- 14Hu H, Xia S-H, Li A-D, et al. "Elevated expression of p63 protein in human esophageal squamous cell carcinomas," (in eng). Int. J. Cancer 2002; 102: 580–3.
- 15Fukushima N, Satoh T, Sueoka N, et al. "Clinico-pathological characteristics of p63 expression in B-cell lymphoma," (in eng). Cancer Sci. 2006; 97: 1050–5.
- 16Moergel M, Abt E, Stockinger M et al. "Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma," (in eng). Oral Oncol. 2010; 46: 667–71.
- 17Hanker L, Karn T, Ruckhaeberle E, et al. "Clinical relevance of the putative stem cell marker p63 in breast cancer," (in eng). Breast Cancer Res. Treat. 2010; 122: 765–75.
- 18Asioli S, Righi A, de Biase D, et al. "Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas," (in eng). Mod. Pathol. 2011; 24: 1451–61.
- 19Dabner M, McClure RJ, Harvey NT, et al. "Merkel cell polyomavirus and p63 status in Merkel cell carcinoma by immunohistochemistry: Merkel cell polyomavirus positivity is inversely correlated with sun damage, but neither is correlated with outcome," (in eng). Pathology 2014; 46: 205–10.
- 20Fleming KE, Ly TY, Pasternak S et al. "Support for p63 expression as an adverse prognostic marker in Merkel cell carcinoma: report on a Canadian cohort," (in eng). Hum. Pathol. 2014; 45: 952–60.
- 21Hall BJ, Pincus LB, Yu SS et al. "Immunohistochemical prognostication of Merkel cell carcinoma: p63 expression but not polyomavirus status correlates with outcome," (in eng). J. Cutan. Pathol. 2012; 39: 911–7.
- 22Higaki-Mori H, Kuwamoto S, Iwasaki T, et al. "Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma," (in eng). Hum. Pathol. 2012; 43: 2282–91.
- 23Stetsenko GY, Malekirad J, Paulson KG, et al. "p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility," (in eng). Am. J. Clin. Pathol. 2013; 140: 838–44.
- 24Vujic I, Marker M, Posch C, et al. "Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression," (in eng). J. Eur. Acad. Dermatol. Venereol. 2015; 29: 542–8.
- 25Liberati A, Altman DG, Tetzlaff J, et al. "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration," (in eng). J. Clin. Epidemiol. 2009; 62: e1–34.
- 26Aromataris E, Fernandez R, Godfrey CM et al. "Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach," (in eng). Int. J. Evid. Based Healthc. 2015; 13: 132–40.
- 27Bichakjian CK, Nghiem P, Johnson T. "Merkel Cell Carcinoma," in AJCC Cancer Staging Manual, MB Amin et al. Eds., 8th ed. Springer International Publishing. New York, NY: American Joint Commission on Cancer, 2017, ch. 46, pp. 549–562.
10.1007/978-3-319-40618-3_46 Google Scholar
- 28Kuwamoto S, Higaki H, Kanai K, et al. "Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma," (in eng). Hum. Pathol. 2011; 42: 632–40.
- 29Paulson KG, Carter JJ, Johnson LG, et al. "Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients," (in eng). Cancer Res. 2010; 70: 8388–97.
- 30Sihto H, Kukko H, Koljonen V et al. "Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma," (in eng). J Natl. Cancer Inst. 2009; 101: 938–45.
- 31Schrama D, Peitsch WK, Zapatka M, et al. "Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma," (in eng). J. Invest. Dermatol. 2011; 131: 1631–8.
- 32Bhatia K, Goedert JJ, Modali R et al. "Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome," (in eng). Int. J. Cancer 2010; 127: 1493–6.
- 33Tan BH, Busam KJ, Pulitzer MP. "Combined intraepidermal neuroendocrine (Merkel cell) and squamous cell carcinoma in situ with CM2B4 negativity and p53 overexpression(*)," (in eng). J. Cutan. Pathol. 2012; 39: 626–30.
- 34Sihto H, Bohling T, Kavola H, et al. "Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study," (in eng). Clin. Cancer Res. 2012; 18: 2872–81.
- 35Moshiri AS, Doumani R, Yelistratova L, et al. "Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive SubtypeBased on Analysis of 282 Cases UsingMultimodal Tumor Virus Detection" (in eng), J. Invest. Dermatol., 2017; 137: 819–27.
- 36Afanasiev OK, Yelistratova L, Miller N, et al. "Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers," (in eng). Clin. Cancer Res. 2013; 19: 5351–60.
- 37Lyngaa R, Pedersen NW, Schrama D, et al. "T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors," (in eng). Clin. Cancer Res. 2014; 20: 1768–78.
- 38Miller NJ, Church CD, Dong L, et al. "Tumor-Infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival," (in eng), Cancer Immunol. Res. 2017; 5: 137–47.
Citing Literature
